Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28). This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results